NASDAQ:CODXCo-Diagnostics Stock Price, Forecast & News

Co-Diagnostics' stock was trading at $13.19 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CODX stock has increased by 36.5% and is now trading at $18.00. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Co-Diagnostics.

Co-Diagnostics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Co-Diagnostics.

Co-Diagnostics Inc (NASDAQ:CODX) issued its earnings results on Thursday, May, 14th. The company reported ($0.05) EPS for the quarter, missing the Zacks' consensus estimate of ($0.04) by $0.01. The company earned $1.55 million during the quarter, compared to analysts' expectations of $1.10 million. Co-Diagnostics had a negative net margin of 334.58% and a negative return on equity of 81.15%. View Co-Diagnostics' earnings history.

Co-Diagnostics issued an update on its fourth quarter earnings guidance on Tuesday, March, 31st. The company provided EPS guidance of ($0.36) for the period, compared to the Thomson Reuters consensus EPS estimate of ($0.09). The company issued revenue guidance of $214.97 million, compared to the consensus revenue estimate of $0.10 million.

2 brokers have issued 12-month price targets for Co-Diagnostics' shares. Their forecasts range from $4.00 to $30.00. On average, they expect Co-Diagnostics' stock price to reach $17.00 in the next twelve months. This suggests that the stock has a possible downside of 5.6%. View analysts' price targets for Co-Diagnostics.

Media headlines about CODX stock have been trending extremely negative on Saturday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Co-Diagnostics earned a media sentiment score of -4.6 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutCo-Diagnostics.

Some companies that are related to Co-Diagnostics include Cantel Medical (CMD), Glaukos (GKOS), Shockwave Medical (SWAV), Cardiovascular Systems (CSII), Luminex (LMNX), Axonics Modulation Technologies (AXNX), Silk Road Medical (SILK), Atrion (ATRI), Tactile Systems Technology (TCMD), Cerus (CERS), Cryolife (CRY), OraSure Technologies (OSUR), Orthopediatrics (KIDS), Orthofix Medical (OFIX) and GenMark Diagnostics (GNMK). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Co-Diagnostics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Moderna (MRNA), Advanced Micro Devices (AMD), Vaxart (VXRT), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU) and Alibaba Group (BABA).

(CODX) raised $9 million in an initial public offering (IPO) on Thursday, July 13th 2017. The company issued 1,300,000 shares at a price of $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities served as the underwriters for the IPO.

Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX."

Co-Diagnostics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Morgan Stanley (1.34%), Morgan Stanley (1.34%), Geode Capital Management LLC (0.44%), Harvest Investment Services LLC (0.24%), IFG Advisory LLC (0.22%) and Wealth Architects LLC (0.15%). View institutional ownership trends for Co-Diagnostics.

CODX stock was sold by a variety of institutional investors in the last quarter, including HighTower Advisors LLC. View insider buying and selling activity for Co-Diagnostics.

CODX stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Geode Capital Management LLC, Harvest Investment Services LLC, IFG Advisory LLC, Wealth Architects LLC, Engineers Gate Manager LP, and Paloma Partners Management Co. View insider buying and selling activity for Co-Diagnostics.

Shares of CODX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CODX stock can currently be purchased for approximately $18.00.

Co-Diagnostics has a market capitalization of $494.28 million and generates $220,000.00 in revenue each year. The company earns $-6,200,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Co-Diagnostics employs 22 workers across the globe.

The official website for Co-Diagnostics is www.codiagnostics.com.

Co-Diagnostics' mailing address is 2401 SOUTH FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT, 84109. The company can be reached via phone at 801-438-1036 or via email at [email protected]